Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biological product manufacturing company that describes its mission as building the tools that make biology easier to engineer. The DNA stock news page on Stock Titan aggregates company announcements, collaborations, and regulatory updates so investors and observers can follow how Ginkgo’s platform is being applied across sectors.
According to Ginkgo’s public statements, its business spans cell engineering services, biosecurity offerings, modular lab automation, large-scale biological data generation, and agricultural biologicals R&D. News about Ginkgo Bioworks often covers new partnerships with academic institutions, biotechnology companies, and government agencies, as well as updates on projects funded by U.S. health and research organizations. These stories illustrate how the company’s R&D Solutions, Automation, Datapoints, Agriculture, and Biosecurity units are used in real-world programs.
Typical Ginkgo Bioworks news items include announcements of research collaborations in areas like cancer screening, drug safety modeling, and in vivo cell and gene therapy; contracts for high-throughput phenotyping platforms and biosecurity-related capabilities; and agreements to optimize fermentation and bioprocesses for agricultural soil amendments and biological crop solutions. Investors can also find information about extended strategic partnerships in agriculture and other markets.
This page may also surface press releases tied to quarterly financial results, conference presentations, and other investor communications referenced in the company’s filings. By reviewing the DNA news feed, users can see how Ginkgo Bioworks positions its platform, how its collaborations evolve over time, and how its activities relate to the broader biological product manufacturing and synthetic biology landscape.
Synlogic, Inc. (Nasdaq: SYBX) announced the development of SYNB2081, a new Synthetic Biotic drug candidate for treating gout, in collaboration with Ginkgo Bioworks (NYSE: DNA). This marks the second drug candidate to enter clinical development through their partnership, following SYNB1353 for homocystinuria. Gout, characterized by high uric acid levels, currently lacks effective treatments. SYNB2081 aims to address this need. The collaboration highlights the innovation potential of synthetic biology in developing therapeutics for various diseases.
On August 11, 2022, Ginkgo Bioworks (NYSE: DNA) and the Rwanda Development Board (RDB) announced a Memorandum of Understanding to enhance biosecurity in Rwanda. This partnership aims to support local public health institutions by providing biosecurity tools, training, and data infrastructure leveraging Ginkgo's Concentric platform. The collaboration intends to address regional biosecurity challenges and lay a foundation for a sustainable bioeconomy, tapping into Rwanda's biodiversity. Ginkgo's initiative reflects a significant step in its global biosecurity strategy.
Ginkgo Bioworks (NYSE: DNA) is scheduled to present its second quarter 2022 results on August 15, 2022, at 4:30 p.m. ET. The session will review the company's business performance for the quarter ending June 30, 2022. Investors can access details and the webcast link on Ginkgo's investor relations website. Additionally, a replay will be available post-event. Ginkgo's platform focuses on programming cells for applications in various sectors including food, agriculture, and pharmaceuticals, and has been active in COVID-19 response efforts.
Ginkgo Bioworks (NYSE: DNA) has appointed Kathy Hopinkah Hannan, PhD, CPA to its Board of Directors, effective August 2, 2022. Dr. Hannan brings over 30 years of experience as a C-Suite executive and corporate advisor, enhancing Ginkgo's leadership at a crucial time in its development. Her background includes significant roles at KPMG LLP and governance positions at various corporations. This strategic addition aims to leverage her expertise in enterprise sustainability and financial advisory, supporting Ginkgo's growth in the synthetic biology industry.
Ginkgo Bioworks (NYSE: DNA) extends its partnership with Clinical Enterprise to support the federal Operation Expanded Testing program, providing no-cost COVID-19 testing through December 31, 2022. This program serves vulnerable communities across the Northeast and South regions of the U.S., including K-12 schools and correctional facilities. With participation from over 1,800 organizations, the initiative aims to enhance testing equity. Key executives expressed commitment to empowering local communities and addressing asymptomatic infections.
Ginkgo Bioworks (NYSE: DNA) has announced a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock deal valued at approximately $300 million. Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share, resulting in a pro forma ownership of 5.25% in the combined entity. This acquisition aims to enhance Ginkgo's horizontal synthetic biology platform through Zymergen's technology and assets, fostering new growth opportunities. The transaction is expected to close by Q1 2023, pending regulatory and stockholder approvals.
Ginkgo Bioworks (NYSE: DNA) has signed a definitive agreement to acquire Bayer's 175,000-square-foot Biologics R&D center for approximately $83 million. This acquisition aims to enhance Ginkgo's agricultural biologicals capabilities. The deal is expected to close in Q4 2022, pending regulatory approvals. Additionally, Ginkgo will enter a three-year collaboration with Bayer, focusing on advancing various agricultural biological programs, including nitrogen fixation. This partnership is anticipated to generate royalty earnings from products developed under the collaboration, potentially offsetting operational costs.
Ginkgo Bioworks (NYSE: DNA) announced a new cell programming project in collaboration with Sumitomo Chemical Co., Ltd. This partnership focuses on producing sustainable, animal-free molecules for the personal care and cosmetic industries. Leveraging Ginkgo's expertise and extensive codebase, the project aims to enhance sustainability while offering competitive advantages in the market. Sumitomo Chemical recognizes the potential of synthetic biology in meeting the growing demand for eco-friendly products. This initiative complements their ongoing collaboration, initiated in 2021, aimed at bio-based production across multiple sectors.
Summary not available.
Cronos Group (NASDAQ: CRON) and Ginkgo Bioworks (NYSE: DNA) have achieved a productivity milestone in their collaboration to produce cultured cannabinoids, specifically tetrahydrocannabivarin (THCV). This development is part of an initiative launched in 2018 aimed at creating rare cannabinoids at industrial scale. Cronos has issued approximately 2.2 million common shares to Ginkgo as a result of this achievement. The partnership underscores both companies' commitment to innovation in the cannabis industry, enhancing Cronos' product pipeline with potential market introductions for THCV.